Pereira Nigel, Frankel William C, Hutchinson Anne P, Patel Hency H, Mostisser Cheri, Elias Rony T
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical Center, New York, NY, USA.
Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA.
Int J Gynaecol Obstet. 2017 Jun;137(3):295-300. doi: 10.1002/ijgo.12128. Epub 2017 Mar 16.
To investigate the temporal trends in minimally invasive myomectomy at one reproductive medicine center before and after the US Food and Drug Administration (FDA) recommendation against electric morcellation.
A retrospective chart review was undertaken of patients undergoing minimally invasive myomectomy between April 1, 2012, and April 30, 2016, at a center in New York. Temporal trends in laparoscopic myomectomy (LM), robot-assisted laparoscopic myomectomy (RAM), and laparoscopically assisted myomectomy (LAM), and intraoperative and postoperative outcomes before and after the April 2014 recommendation were compared.
Minimally invasive myomectomy was performed in 73 patients. No difference was noted in the rates of minimally invasive myomectomy 2 years before (35/74 [47.3%]) and after (38/79 [48.1%]) the FDA's recommendation. The ratio of abdominal to minimally invasive myomectomy remained relatively constant before (68/59=1.15) and during the study period (80/73=1.10). There was a significant decrease in LM and RAM and a corresponding rise in LAM immediately after the recommendation (P<0.001).
The rates of minimally invasive myomectomy before and after the FDA's recommendation did not differ, indicating that technical modifications to laparoscopic technique can allow surgeons to offer minimally invasive myomectomy to patients with symptomatic leiomyomas.
调查在美国食品药品监督管理局(FDA)发布反对电动粉碎术的建议前后,某生殖医学中心微创子宫肌瘤切除术的时间趋势。
对2012年4月1日至2016年4月30日在纽约某中心接受微创子宫肌瘤切除术的患者进行回顾性病历审查。比较2014年4月建议前后腹腔镜子宫肌瘤切除术(LM)、机器人辅助腹腔镜子宫肌瘤切除术(RAM)和腹腔镜辅助子宫肌瘤切除术(LAM)的时间趋势,以及术中及术后结果。
73例患者接受了微创子宫肌瘤切除术。FDA建议前两年(35/74 [47.3%])和建议后(38/79 [48.1%])的微创子宫肌瘤切除率无差异。腹部子宫肌瘤切除术与微创子宫肌瘤切除术的比例在研究前(68/59 = 1.15)和研究期间(80/73 = 1.10)保持相对稳定。建议发布后,LM和RAM显著减少,LAM相应增加(P<0.001)。
FDA建议前后的微创子宫肌瘤切除率没有差异,这表明腹腔镜技术的技术改进可以使外科医生为有症状的平滑肌瘤患者提供微创子宫肌瘤切除术。